您的位置： &
& 区马多吃多会怎么样啊
区马多吃多会怎么样啊
问：......
答：你好。你的情况建议最好是戒除一年以后再考虑怀孕比较安全的。&&&&一定要间隔一年以后才可以考虑怀孕的 &&......
问：病情描述（主要症状、发病时间）:&&我吃桂枝茯苓胶囊和盐酸克林霉素胶囊三天后，胃脘有顶感脘区隐痛舌苔有奌润白。停药已有两天，症状并未消失，吃钣无味，嘴......
答：病情分析：你好，根据你的咨询考虑反流性胃炎或者食管炎引起的症状，需要胃镜检查和服用药物。指导意见：看服用吗叮啉片和奥美拉唑胶囊以及胃康灵胶囊治疗。另外不能吃辛辣刺激性食物和不能吸烟喝酒。需要少食多餐和规律饮食。祝健康。医生询问：&&nbsp......
问：病情描述（主要症状、发病时间）:&&时痛时不痛
&&曾经治疗情况和效果:&&三年前在四医大做造影为心肌桥，吃辛......
答：病情分析：你好，你的情况还是由于心脏供血不足引起的症状，一般会引起心前区疼痛和心慌气短和腹胀等症状的，你的情况需要积极药物治疗的指导意见：你的情况我建议首先就要注意休息，清淡温热易消化饮食很重要的，建议你积极服药治疗，比如服用麝香保心丸和复方丹参片和......
问：了而我吃药吃了三年‘&&曾经治疗情况和效果:&&目前医生说是健康的我好害怕‘毕竟不能彻底查清楚&&想得到怎样的......
答：病情分析：&& 你好，曲马多是一种止痛性的药物，一般的对于胎儿影响不大的。既然医生检查是正常的，那么孩子基本是没有问题的。&&指导意见：&& 这个你暂时不要过于担心，一般的没事的，注意保持良......
问：吃卡马吃卡马西平片可以怀孕吗西平片有啥副作用......
答：宝宝只要是在胚胎以前没有完全的形成是没关系，不会影响的哦!六周宝宝已经有心跳了!其实八周左右就可以先去看!去听宝宝的心跳，不要太担心!&&&&......
问：病情描述（主要症状、发病时间）:&&胃脘有顶感 脘区隐痛 舌苔有奌润白 吃钣无味，有吋有胃酸。易感冒。
&&曾经治疗情况和效果:&......
答：您好，这是胃炎的症状建议你做胃镜检查，确诊后服用奥美拉唑,吗丁啉和胃炎颗粒治疗,&&......
问：......
答：毛囊炎的病原菌主要是金黄色葡萄球菌，偶有表皮葡萄球菌、链球菌、假单孢菌属和类大肠杆菌。毛发的牵拉、摩擦、搔抓引起的损伤，保持皮肤清洁卫生，限制辛辣刺激性食物。外用，涂敷患处，每日数次。 &&......
问：......
答：这个要看是否打错药物名字，这个一般按说明吃就好了。&&......
问：......
答：根据你的情况分析，一般还是可以试试的，基本没有配伍禁忌，一般问题不大&&......
问：......
答：这个可以吃叶酸片，不要吃另外的蛋白，这个会有副作用的你吃到的不是你知道的东西。&&......
问：......
答：吃叶酸就行了，不要吃别的就可以。这个没什么好处的。&&......
问：你好，09年手术食管癌至今在吃马来西亚‘优楯草。现在还是显瘦。请问有的治吗.......
答：你好，你说的情况最好采用有效的传统中药巩固治疗，有可能康复，许多患者康复后能够长期存活。中医中药长期临床实践积累了许多非常有效的治疗方法，建议你用虫草、猪苓、明党参、桑寄生、青阳参、香菇、红豆蔻、桑白皮、杜仲、降香、茯苓、白术、八月札、知母、片姜黄、......
问：病情描述（主要症状、发病时间）:&&月经干净第一天同房，隔天吃了紧急避孕药，过了三天出血像来月经一样。这是怎么了。
&&曾经治疗情......
答：病情分析：您好，是服用避孕药引起的。指导意见：服用避孕药引起的撤退性出血，是正常的，不用担心。&&......
问：真性细胞下降后不久又增多了，只按疗程吃马法兰吗？......
答：你好，这个情况需要看看医生，根据情况需要调节药量的 提问人的追问
11:39:01就只吃马法兰，其他的治疗都没有了吗？&&......
更多相关推荐
收藏快速问医生，随时免费咨询和挂号真性红细胞增多症打完干扰素后白细胞下降厉害正常吗_百度知道
真性红细胞增多症打完干扰素后白细胞下降厉害正常吗
提问者采纳
也不能做到平衡，也就是适当减少干扰素的用量，就需要调整药物剂量，平衡药物用量，比如改为口服羟基脲或马法兰，会不可避免的“误杀”白细胞和血小板。干扰素在“杀”增多的红细胞时，又不至于对白细胞及血小板影响太大。这时候就需要考虑换药。
但是有时个别人即使经过上述调整，导致二者出现下降，使之既能控制红细胞。遇到这种情况时这种情况很正常
其他类似问题
白细胞的相关知识
等待您来回答
下载知道APP
随时随地咨询
出门在外也不愁马法兰针（爱克兰、Melphalan、Alkeran）-药品说明书与价格-中国新特药网天津站
当前位置： >>
马法兰针（爱克兰、Melphalan、Alkeran）
马法兰针（爱克兰、Melphalan、Alkeran）
14:01:55&&作者：&&来源：&&浏览次数：900&&文字大小：【】【】【】
简介：马法兰针（爱克兰、Melphalan、Alkeran） Melphalan Alkeran 50mg/vial适应症：Ovaries cancer, Breast cancer, Testicular cancer, Multiple myeloma, Sarcomas, melanoma给药途径：IV infusion (以NS稀释) 稀 ...关键字：
马法兰针（爱克兰、Melphalan、Alkeran） Melphalan Alkeran 50mg/vial适应症：Ovaries cancer, Breast cancer, Testicular cancer, Multiple myeloma, Sarcomas, melanoma给药途径：IV infusion (以NS稀释) 稀释浓度：≦ 0.45mg/ml，以0.1mg/ml為佳注射时间： 30 分鐘 稀释后浓度不稳定，大约每10分鐘水解10%，尽量於使用前再稀释药品 毒性及副作用： 骨髓抑制(Myelosuppression)：白血球减少症(Leukopenia)及血小板减少症(thrombocytopenia) 於第21天减少到最低，老人甚至於使用药物5~6週，其值还是很低 噁心、呕吐；口角炎、腹泻在一般剂量较少发生 肺部纤维化(Fibrosis)、间质性浸润(Interstitial infiltrates)发生机率罕见 秃发：於高剂量时较常发生 过敏反应：发生率10%，过敏、发汗(diaphoresis)、低血压、心跳过快、支气管痉挛、呼吸困难、心跳停止 长期口服使用此药，约10%病人发展成第二种癌症，如急性骨髓母细胞白血病(acute myelogenous leukemia)、及髓发育不良症安定性：此药经过调配后於室温下，立即使用，不可冷藏 避光贮存 病患教育： 对此药过敏，请不要服用此药品 避免饮酒 避免服用Aspirin(Tapal&)或感冒药，需告知医师 接受疫苗注射前，需告知医师 容易感染，需避免到公共场所及预防感冒等 不要哺乳、怀孕，接受此药后可能会造成不孕 易有口腔发炎、疮及刺刺的感觉，口腔清洁需彻底 若要预防噁心、呕吐，可请医师开立止吐药处方 医师可能会為病人抽血检查血球 病患须知的副作用： 发烧、冷颤、喉咙痛 不寻常的流血、挫伤 漏失几次月经 口腔发炎时，避免饮水；或改以吸管喝水 严重腹泻 皮肤红潮、荨麻疹 呼吸困难 下列副作用，请询问医师：食慾不振、掉发 .
马利兰为磺酸类烷化剂；在体内解离为活泼不稳定的离子产生烷化作用而毒害细胞，为细胞周期非特异性药物。适用于慢性粒细胞白血病，真性红细胞增多症，原发性血小板增多症，骨髓纤维化。
【马利兰药理作用】
马利兰为磺酸类烷化剂；在体内解离为活泼不稳定的离子产生烷化作用而毒害细胞，为细胞周期非特异性药物。对多种肿瘤均有抑制作用，在较低剂量时主要影响骨髓粒细胞的生成，对淋巴组织几乎无影响。所以本品临床主要用于治疗慢性粒细胞白血病及真性红细胞增多症、骨髓纤维化等。大剂量可抑制血小板和红细胞。
【马利兰临床疗效】
使用马利兰及羟基脲治疗后患者症状有所改善、脾脏缩小及血液中白细胞数下降，CNL是一种少见类型的慢性白血病,其特点与慢性髓细胞白血病不同;马利兰及羟基脲对其有一定疗效;预后具有异质性。
有研究表明，HU较 BU作用快、疗效好，副作用小。HU应作为治疗 CML的首选药物。
【马利兰不良反应】
主要不良反应是骨髓抑制，尤其是血小板减少。
胃肠道：恶心、呕吐和腹泻在正常治疗剂量时少见，分次服用可减轻反应。
肺：少数患者发生约弥漫性肺纤维化，伴随进行性持续呼吸困难及干咳，常见于数年长期用药者。组织学特点为肺泡和细支气管上皮不典型改变，可见有大而深染核的巨细胞。一旦发生肺毒笥，即使停药，预后也不良；使用类固醇激素几乎无效。肺损害通常隐匿进展，但有时也可呈急性发作。如伴随感染，可使肺的病理学变化更趋复杂。有肺骨化和异位钙化的报告。随后的放疗可能加重由马利兰引起的亚临床肺损伤。其它联合使用的细胞毒药物也可加重肺毒性。
皮肤：色素沉着过多是最常见的皮肤反应，特别是肤色较深的患者，发生率为5～10%。颈部、上半身、乳头、腹部、掌面等的皱褶处色素沉最为明显。少数长期使用马利兰的患者，色素沉着过多成为一种类似于肾上腺功能不全（艾狄森病）的临床综合征的一部分。此综合征的特点为虚弱、严重乏力、厌食、消瘦、恶心、呕吐以及皮肤色素过多沉着，但无肾上腺损害的生化变化或黏膜色素沉着过多或毛发减少。有时停用马利兰后，此综合征可消失。其它罕见的皮肤反应包括荨麻疹、多形红斑、结节性红斑、脱发、特异性卟啉症皮肤损害、别嘌呤醇型皮疹、完全脱水的过度干燥和变脆的皮肤、口腔黏膜干燥和唇干裂，也有并发干燥综合征（Sjogren's Syndrome）的报告。在用大剂量马利兰治疗后，立即进行放疗的患者，其皮肤放疗反应可加重。
肝：偶有报告发生胆汁淤积性黄疸及肝功能异常。但在正常治疗剂量下，显著的肝毒性并不常见。然而，用低剂量马利兰2年或2年以上的慢性粒细胞白血病例的回顾性尸检报告显示，肝小叶中央窦状隙纤维化。马利兰和硫嘌呤合用，可发生明显的肝毒性。高胆红素血症、黄疸、肝静脉闭塞和肝小叶中央窦状隙纤维伴肝细胞萎缩和坏死，可见于大剂量马利兰治疗的患者。
眼：有报告在马利兰治疗期间发生晶状体改变和白内障，并可累及双侧眼球。有报告接受大剂量马利兰治疗后再进行骨髓称植的患者，可导致角膜变薄。
其它：成人使用大剂量马利兰有发生惊厥的报告。少数地中海贫血患者服用大剂量马利兰后，曾出现心压塞。有发现应用马利兰后，发生男性乳房发育、重症肌无力和出血性膀胱炎。组织学和细胞学变化，包括子宫颈、支气管和其它脏器上皮的广泛异常增生，大多见于长期用药者。但暂时性上皮异常也可见于短期大剂量用药者。
禁 忌：耐药者不宜使用本品；对本品任何成分过敏者禁用。
注意事项：
马利兰是一种细胞毒药物，只限于在对此类药物有经验的内科医师指导下应用。如发生肺毒性，应停止使用。服用马利兰期间，通常不宜同时进行放疗；也不应在放疗后立即应用本品。当出现未成熟细胞转化时，马利兰已无效。可能有肺毒性的患者需麻醉时，应吸入尽可能低浓度的氧、以保证安全。术后应进行呼吸监护。慢性粒细胞白血病伴高尿酸症和/高尿酸血症并非少见。故在开始马利兰治疗前，应予纠正。在治疗期间，应积极预防高尿酸血症和尿酸性肾病发生，包括充分的水摄入及服用别嘌呤醇。鉴于马利兰具有潜在的致癌危险，故用于真性红细胞增多症及原发性血小板增多症时应慎重考虑。年轻患者会无症状，应避免使用。如确需治疗，应尽量缩短疗程。患者在接受马利兰治疗时，如合用全身性伊曲康唑，应监测白消安的细胞毒作用的反应。
用法用量：
通则：马利兰通常按疗程给药或连续用药，用药剂量必须在严格的临床和血液学监控下介体化调节。如患者所需的平均日剂量低于马利兰片的现有规格，可通过减少给药天数（1天或数天）来调节，不可将药片掰开。口服：每次2mg，每日2～4次。待白细胞降至1万/mm3左右时停药或改为维持量；每次1～3mg，每日1次或1周2次。也可间歇用药，2～3日服6-8mg，直至白细胞下降至正常时停药。或遵医嘱。
WARNINGSMelphalan should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation. Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.DESCRIPTIONMelphalan, also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent that is active against selected human neoplastic diseases. It is known chemically as 4-[bis(2-chloroethyl)amino]-L-phenylalanine.Melphalan is the active L-isomer of the compound and was first synthesized in 1953 by Bergel and S the D-isomer, known as medphalan, is less active against certain animal tumors, and the dose needed to produce effects on chromosomes is larger than that required with the L-isomer. The racemic (DL-) form is known as merphalan or sarcolysin.Melphalan is practically insoluble in water and has a pKa1 of ~2.5.ALKERAN for Injection is supplied as a sterile, nonpyrogenic, freeze-dried powder. Each single-use vial contains melphalan hydrochloride equivalent to 50 mg melphalan and 20 mg povidone. ALKERAN for Injection is reconstituted using the sterile diluent provided. Each vial of sterile diluent contains sodium citrate 0.2 g, propylene glycol 6.0 mL, ethanol (96%) 0.52 mL, and Water for Injection to a total of 10 mL. ALKERAN for Injection is administered intravenously.CLINICAL PHARMACOLOGYMelphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N7 position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.PharmacokineticsThe pharmacokinetics of melphalan after IV administration has been extensively studied in adult patients. Following injection, drug plasma concentrations declined rapidly in a biexponential manner with distribution phase and terminal elimination phase half-lives of approximately 10 and 75 minutes, respectively. Estimates of average total body clearance varied among studies, but typical values of approximately 7 to 9 mL/min/kg (250 to 325 mL/min/m2) were observed. One study has reported that on repeat dosing of 0.5 mg/kg every 6 weeks, the clearance of melphalan decreased from 8.1 mL/min/kg after the first course, to 5.5 mL/min/kg after the third course, but did not decrease appreciably after the third course. Mean (+/-SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m2 were 1.2 +/- 0.4 and 2.8 +/- 1.9 mcg/mL, respectively.The steady-state volume of distribution of melphalan is 0.5 L/kg. Penetration into cerebrospinal fluid (CSF) is low. The extent of melphalan binding to plasma proteins ranges from 60% to 90%. Serum albumin is the major binding protein, while α1-acid glycoprotein appears to account for about 20% of the plasma protein binding. Approximately 30% of the drug is (covalently) irreversibly bound to plasma proteins. Interactions with immunoglobulins have been found to be negligible.Melphalan is eliminated from plasma primarily by chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan. Aside from these hydrolysis products, no other melphalan metabolites have been observed in humans. Although the contribution of renal elimination to melphalan clearance appears to be low, one study noted an increase in the occurrence of severe leukopenia in patients with elevated BUN after 10 weeks of therapy.INDICATIONS AND USAGEALKERAN for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.CONTRAINDICATIONSMelphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. Patients who have demonstrated hypersensitivity to melphalan should not be given the drug.WARNINGSALKERAN for Injection may cause local tissue damage should extravasation occur, and consequently it should not be administered by direct injection into a peripheral vein. It is recommended that ALKERAN for Injection be administered by injecting slowly into a fast-running IV infusion via an injection port, or via a central venous line (see DOSAGE AND ADMINISTRATION: Administration Precautions).Melphalan should be administered in carefully adjusted dosage by or under the supervision of experienced physicians who are familiar with the drug's actions and the possible complications of its use. As with other nitrogen mustard drugs, excessive dosage will produce marked bone marrow suppression. Bone marrow suppression is the most significant toxicity associated with ALKERAN for Injection in most patients. Therefore, the following tests should be performed at the start of therapy and prior to each subsequent dose of ALKERAN: platelet count, hemoglobin, white blood cell count, and differential. Thrombocytopenia and/or leukopenia are indications to withhold further therapy until the blood counts have sufficiently recovered. Frequent blood counts are essential to determine optimal dosage and to avoid toxicity. Dose adjustment on the basis of blood counts at the nadir and day of treatment should be considered.Hypersensitivity reactions including anaphylaxis have occurred in approximately 2% of patients who received the IV formulation (see ADVERSE REACTIONS). These reactions usually occur after multiple courses of treatment. Treatment is symptomatic. The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. If a hypersensitivity reaction occurs, IV or oral melphalan should not be readministered since hypersensitivity reactions have also been reported with oral melphalan.CarcinogenesisSecondary malignancies, including acute nonlymphocytic leukemia, myeloproliferative syndrome, and carcinoma, have been reported in patients with cancer treated with alkylating agents (including melphalan). Some patients also received other chemotherapeutic agents or radiation therapy. Precise quantitation of the risk of acute leukemia, myeloproliferative syndrome, or carcinoma is not possible. Published reports of leukemia in patients who have received melphalan (and other alkylating agents) suggest that the risk of leukemogenesis increases with chronicity of treatment and with cumulative dose. In one study, the 10-year cumulative risk of developing acute leukemia or myeloproliferative syndrome after oral melphalan therapy was 19.5% for cumulative doses ranging from 730 to 9,652 mg. In this same study, as well as in an additional study, the 10-year cumulative risk of developing acute leukemia or myeloproliferative syndrome after oral melphalan therapy was less than 2% for cumulative doses under 600 mg. This does not mean that there is a cumulative dose below which there is no risk of the induction of secondary malignancy. The potential benefits from melphalan therapy must be weighed on an individual basis against the possible risk of the induction of a second malignancy.Adequate and well-controlled carcinogenicity studies have not been conducted in animals. However, intraperitoneal (IP) administration of melphalan in rats (5.4 to 10.8 mg/m2) and in mice (2.25 to 4.5 mg/m2) 3 times per week for 6 months followed by 12 months post-dose observation produced peritoneal sarcoma and lung tumors, respectively.MutagenesisMelphalan has been shown to cause chromatid or chromosome damage in humans. Intramuscular administration of melphalan at 6 and 60 mg/m2 produced structural aberrations of the chromatid and chromosomes in bone marrow cells of Wistar rats.Impairment of FertilityMelphalan causes suppression of ovarian function in premenopausal women, resulting in amenorrhea in a significant number of patients. Reversible and irreversible testicular suppression have also been reported.PregnancyPregnancy Category D. Melphalan may cause fetal harm when administered to a pregnant woman. While adequate animal studies have not been conducted with IV melphalan, oral (6 to 18 mg/m2/day for 10 days) and IP (18 mg/m2) administration in rats was embryolethal and teratogenic. Malformations resulting from melphalan included alterations of the brain (underdevelopment, deformation, meningocele, and encephalocele) and eye (anophthalmia and microphthalmos), reduction of the mandible and tail, as well as hepatocele (exomphaly). There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.PRECAUTIONSGeneralIn all instances where the use of ALKERAN for Injection is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse events. Melphalan should be used with extreme caution in patients whose bone marrow reserve may have been compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.Dose reduction should be considered in patients with renal insufficiency receiving IV melphalan. In one trial, increased bone marrow suppression was observed in patients with BUN levels 30 mg/dL. A 50% reduction in the IV melphalan dose decreased the incidence of severe bone marrow suppression in the latter portion of this study.Administration of live vaccines to immunocompromised patients should be avoided.DOSAGE AND ADMINISTRATIONThe usual IV dose is 16 mg/m2. Dosage reduction of up to 50% should be considered in patients with renal insufficiency (BUN 30 mg/dL) (see PRECAUTIONS: General). The drug is administered as a single infusion over 15 to 20 minutes. Melphalan is administered at 2-week intervals for 4 doses, then, after adequate recovery from toxicity, at 4-week intervals. Available evidence suggests about one third to one half of the patients with multiple myeloma show a favorable response to the drug. Experience with oral melphalan suggests that repeated courses should be given since improvement may continue slowly over many months, and the maximum benefit may be missed if treatment is abandoned prematurely. Dose adjustment on the basis of blood cell counts at the nadir and day of treatment should be considered.Administration PrecautionsAs with other toxic compounds, caution should be exercised in handling and preparing the solution of ALKERAN. Skin reactions associated with accidental exposure may occur. The use of gloves is recommended. If the solution of ALKERAN contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water.Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If either occurs, do not use this product.Care should be taken to avoid possible extravasation of melphalan and in cases of poor peripheral venous access, consideration should be given to use of a central venous line (see WARNINGS).Preparation for Administration/Stability
ALKERAN for Injection must be reconstituted by rapidly injecting 10&mL of the supplied diluent directly into the vial of lyophilized powder using a sterile needle (20-gauge or larger needle diameter) and syringe. Immediately shake vial vigorously until a clear solution is obtained. This provides a 5-mg/mL solution of melphalan. Rapid addition of the diluent followed by immediate vigorous shaking is important for proper dissolution.
Immediately dilute the dose to be administered in 0.9% Sodium Chloride Injection, USP, to a concentration not greater than 0.45&mg/mL.
Administer the diluted product over a minimum of 15&minutes.
Complete administration within 60&minutes of reconstitution.
The time between reconstitution/dilution and administration of ALKERAN should be kept to a minimum because reconstituted and diluted solutions of ALKERAN are unstable. Over as short a time as 30 minutes, a citrate derivative of melphalan has been detected in reconstituted material from the reaction of ALKERAN with Sterile Diluent for ALKERAN. Upon further dilution with saline, nearly 1% label strength of melphalan hydrolyzes every 10 minutes.A precipitate forms if the reconstituted solution is stored at 5°C. DO NOT REFRIGERATE THE RECONSTITUTED PRODUCT.HOW SUPPLIEDALKERAN for Injection is supplied in a carton containing one single-use clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10-mL clear glass vial of sterile diluent (NDC ).Store at controlled room temperature 15° to 30°C (59° to 86°F) and protect from light.
メルファラン（アルキル化剤）商品名（製造・販売会社）
アルケラン（グラクソ・スミスクライン） 多発性骨髄腫では第一選択薬とされ、主な併用療法としては、プレドニゾロンとの併用によるMP療法や、それにシクロホスファミドとラニムスチンを加えたMCMP両方などがあります。
骨髄機能に障害を起こしやすい薬であるという特徴を利用して、造血幹細胞移植の前処置として、患者のがん細胞や骨髄細胞を破壊する際にも用いられます。
適応となるがん多発性骨髄腫では、本剤とプレドニゾロンを併用するMP療法が行われています。また白血病、悪性リンパ腫、多発性骨髄腫、小児固形がんの造血幹細胞移植の前処置にも投与されます。
主な副作用吐き気・嘔吐、下痢、口内炎のほかに骨髄抑制が強く現れます。造血幹細胞移植の前処置などで大量投与すると、呼吸困難や蕁麻疹などのアナフィラキシー症状、間質性肺炎、溶血性貧血を起こすことがあるほか、肝臓障害が生じて黄疸が現れることがあります。
使用上の注意点腎障害があると、副作用が強く出る可能性があります。とくに多発性骨髄腫は、高齢者に多い病気で、腎機能が低下していることが多いので注意が必要です。
责任编辑：
本文引用地址：&
　　　　　
中国新特药天津站--提供国际药讯&& 购买请咨询：022- 本站药品我院多数有现货以及及时调货，如果没有货或是价格有变，不做另外通知，请电话咨询为准。
（）&& 银屑病（牛皮癣）专家咨询电话：022-
本站药品仅供参考，购药时凭医生处方或医嘱用药
在线咨询：}